Search research articles
Contact Us
Filters
Showing results (71-80 of 83) with videos related to
Page
of 9
Sort By:
Scientific Reports
|
May 20, 2022
The impact of endoscopic activity on musculoskeletal disorders of high-volume endoscopists in Germany
N Sturm, J Leukert, L Perkhofer, et al.
BMC Cancer
|
October 25, 2019
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
L Perkhofer, A W Berger, A K Beutel, et al.
British Journal of Cancer
|
August 22, 2013
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
T Hoehler, G von Wichert, C Schimanski, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Changes in survival of >3800 patients with metastatic colorectal cancer in Germany: results from a 16-year prospective longitudinal real-world data analysis
N Marschner, T Seufferlein, K Potthoff, et al.
Scientific Reports
|
September 15, 2019
Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information
T J Ettrich, D Schwerdel, A Dolnik, et al.
Zeitschrift Fur Gastroenterologie
|
March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]
M P Ebert, C Auernhammer, K Caca, et al.
Journal of Cancer Research and Clinical Oncology
|
May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
A Kurreck, M Geissler, U M Martens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method
M Haas, D T Waldschmidt, M Stahl, et al.
ESMO Open
|
February 5, 2022
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
S F Kruger, A Lohneis, A Abendroth, et al.
ESMO Open
|
June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 83) with videos related to
Sort By:
Page
of 9
Scientific Reports
|
May 20, 2022
The impact of endoscopic activity on musculoskeletal disorders of high-volume endoscopists in Germany
N Sturm, J Leukert, L Perkhofer, et al.
BMC Cancer
|
October 25, 2019
Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study
L Perkhofer, A W Berger, A K Beutel, et al.
British Journal of Cancer
|
August 22, 2013
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
T Hoehler, G von Wichert, C Schimanski, et al.
ESMO Real World Data and Digital Oncology
|
February 6, 2026
Changes in survival of >3800 patients with metastatic colorectal cancer in Germany: results from a 16-year prospective longitudinal real-world data analysis
N Marschner, T Seufferlein, K Potthoff, et al.
Scientific Reports
|
September 15, 2019
Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information
T J Ettrich, D Schwerdel, A Dolnik, et al.
Zeitschrift Fur Gastroenterologie
|
March 10, 2009
[Gastrointestinal oncology - therapy update 2008 / 2009]
M P Ebert, C Auernhammer, K Caca, et al.
Journal of Cancer Research and Clinical Oncology
|
May 26, 2020
Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
A Kurreck, M Geissler, U M Martens, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 15, 2021
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method
M Haas, D T Waldschmidt, M Stahl, et al.
ESMO Open
|
February 5, 2022
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
S F Kruger, A Lohneis, A Abendroth, et al.
ESMO Open
|
June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022
M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Page
of 9